IP Library Granted Patent US 8,173,707
Granted Patent B2
US 8,173,707 · App. 12/799,981 · Granted May 8, 2012

Ophthalmologic irrigation solutions and method

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,173,707
App. No.
12/799,981
Granted
May 8, 2012
Kind
B2
Abstract

Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.

Claims (11)

1. A method for perioperatively inhibiting ocular inflammation and maintaining mydriasis during an intraocular ophthalmologic procedure, comprising irrigating intraocular tissues during an intraocular ophthalmologic procedure with a solution including at least an anti-inflammatory agent and a mydriatic agent in a liquid irrigation carrier, wherein the anti-inflammatory agent comprises ketorolac and the mydriatic agent comprises phenylephrine and each of the agents is included in a therapeutically effective amount for the inhibition of inflammation and maintenance of mydriasis when delivered intraocularly during the intraocular ophthalmologic procedure.

2. The method of claim 1 , wherein the ketorolac is included in the solution at a concentration of no more than 100,000 nanomolar and the phenylephrine is included in the solution at a concentration of no more than 500,000 nanomolar.

3. The method of claim 1 , wherein the solution is continuously applied to the intraocular tissues during the intraocular procedure.

4. The method of claim 1 , wherein the liquid irrigation carrier further comprises an adjuvant selected from electrolytes sufficient to provide a physiological balanced salt solution, a cellular energy source, a buffering agent, a free-radical scavenger and mixtures thereof.

5. The method of claim 4 , wherein: the electrolytes, if selected, comprise from 50 to 500 millimolar sodium ions, from 0.1 to 50 millimolar potassium ions, from 0.1 to 5 millimolar calcium ions, from 0.1 to 5 millimolar magnesium ions, from 50 to 500 millimolar chloride ions, and from 0.1 to 10 millimolar phosphate; the buffer, if selected, comprises bicarbonate at a concentration of from 10 to 50 millimolar; the cellular energy source if selected, is selected from dextrose and glucose and is present at a concentration of from 1 to 25 millimolar; and the free-radical scavenger, if selected, comprises glutathione at a concentration of from 0.05 to 5 millimolar.

6. The method of claim 1 , wherein the liquid irrigation carrier further comprises electrolytes sufficient to provide a physiological balanced salt solution, a cellular energy source, a buffering agent and a free-radical scavenger.

7. The method of claim 1 , wherein the pH of the irrigation solution is between 5.5 and 8.0.

8. A method for perioperatively inhibiting ocular inflammation and maintaining mydriasis during an intraocular ophthalmologic procedure, comprising irrigating intraocular tissues during an intraocular ophthalmologic procedure with a solution including at least an anti-inflammatory agent and a mydriatic agent in a liquid irrigation carrier, wherein the anti-inflammatory agent comprises ketorolac and the mydriatic agent comprises phenylephrine and each of the agents is included in a therapeutically effective amount for the inhibition of inflammation and maintenance of mydriasis when delivered intraocularly during the intraocular ophthalmologic procedure, wherein each of the agents contributes to the maintenance of intraoperative mydriasis by providing for mydriasis or inhibiting miosis.

9. The method of claim 8 , wherein the ketorolac is included in the solution at a concentration of no more than 100,000 nanomolar and the phenylephrine is included in the solution at a concentration of no more than 500,000 nanomolar.

10. The method of claim 8 , wherein the solution is continuously applied to the intraocular tissues during the intraocular procedure.

11. The method of claim 8 , wherein the liquid irrigation carrier further comprises electrolytes sufficient to provide a physiological balanced salt solution.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2024
From: RAYNER SURGICAL GROUP LIMITED
To: RAYNER INTRAOCULAR LENSES LIMITED
Reel/Frame 068708/0933 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2024
From: MACULA BIDCO LIMITED
To: RAYNER SURGICAL GROUP LIMITED
Reel/Frame 068696/0334 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2024
From: RAYNER SURGICAL (IRELAND) LIMITED
To: MACULA BIDCO LIMITED
Reel/Frame 068182/0732 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2023
From: RAYNER SURGICAL INC.
To: RAYNER SURGICAL (IRELAND) LIMITED
Reel/Frame 063880/0572 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S COUNTRY PREVIOUSLY RECORDED AT REEL: 059353 FRAME: 0191. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded May 19, 2022
From: OMEROS CORPORATION
To: RAYNER SURGICAL INC.
Reel/Frame 060129/0607 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2022
From: OMEROS CORPORATION
To: RAYNER SURGICAL INC.
Reel/Frame 059353/0191 →
RELEASE OF SECURITY INTEREST Recorded Nov 15, 2018
From: CRG SERVICING LLC
To: OMEROS CORPORATION
Reel/Frame 047573/0577 →
SECURITY INTEREST Recorded Nov 7, 2016
From: OMEROS CORPORATION
To: CRG SERVICING LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 040575/0110 →